The Brampton Prostate Cancer Support group has posted their October presentation and you can view it as below:
Video is now available of their Prostate Cancer Connections webinar on Genetics, Genomics, and Prostate Cancer. This important webinar was recorded on October 15th and features a panel of experts and a patient perspective segment. You can access the video now at https://youtu.be/WjkAF1xixOA.
Here is a link to Four Interesting Prostate Cancer Awareness Month (September) presentations from the Prostate Cancer Foundation of BC:
An update on an October presentation:
A note to anyone who tried to reach the October 13th presentation by Dr. Jeffrey Campbell on “Erectile Dysfunction and Urinary Incontinence after Prostate Cancer Treatment” put on by the Windsor / Essex PCS group. They offer their apologies as the link to the talk was changed at the last minute and caught them off guard. They are attempting to schedule a re-run of Dr. Campbell’s excellent presentation in November and we will let you know once they have arranged it.
Some Interesting Articles & Presentations
Walter Eadie of the Oakville / Mississauga Prostate Cancer Support group has sent along some suggested items on prostate cancer:
Here is a summary of the interesting papers and articles he has read recently:
Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a Phase 3 clinical trial. However, that new trial analysis showed there were no such benefits to ADT therapy for men with favorable intermediate-risk prostate cancer undergoing radiation therapy. These findings support the National Comprehensive Cancer Network recommendations that ADT treatment only be given to patients with unfavorable intermediate-risk prostate cancer.
A new artificial intelligence (AI) algorithm has been developed that can accurately detect and grade prostate cancer, using slide images from patient core needle prostate biopsies, a study reports. An AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking comparable to that of international experts in prostate pathology. https://pubmed.ncbi.nlm.nih.gov/31926806/
“This is going to change everything.” Soon, you will find out your lifetime risk of getting prostate cancer through a simple saliva or blood test.
“The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic recurrence of their cancer.”
Note, fluciclovine (brand name Axumin) is FDA approved for use in PC. PSMA/PET, which is claimed to be even better, is not yet approved but that is expected within months.
Expanding on the above – here is a recording of the best review of PSMA/PET imaging that I have seen – how and when it can be used and how it can change the treatment plan for a patient
Here is something coming up on the same topic from the support community in the U. S.
Prostate Cancer Connections, Imaging and Prostate Cancer Webinar
Tuesday, November 24, 2020 7:00-8:30pm Central
Register at: www.ustoo.org/connections